{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:18:34Z","timestamp":1791839914599,"version":"4.3.4"},"reference-count":81,"publisher":"Societatea Romana de Morfologie","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2025,2,20]]},"abstract":"<jats:p>Toxic epidermal necrolysis (TEN) is a serious dermatological condition often triggered by different drugs or medications or, less commonly, by infections, leading to extensive epidermal detachment and multisystemic complications, resembling the severity and systemic impact of burn injuries. This case report portrays a 26-year-old female patient with a history of psychiatric treatment and recreational drug use, presenting with typical prodromal symptoms and characteristic manifestations on the integument and mucosae. Clinical management involved an interdisciplinary team in a burn center, administering immunoglobulins, systemic steroids, and supportive therapies to prevent complications including infection and to support skin re-epithelization. Histopathological findings confirmed the diagnosis. Despite the extensive lesions, prompt treatment facilitated a positive outcome. The report emphasizes the necessity of referral to specialized centers and the complex, multidisciplinary management required for TEN patients to optimize survival and minimize long-term sequelae.<\/jats:p>","DOI":"10.47162\/rjme.65.4.23","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T10:37:15Z","timestamp":1740652635000},"page":"765-773","source":"Crossref","is-referenced-by-count":4,"title":["Toxic epidermal necrolysis \u2013 clinicopathological aspects and therapeutic management"],"prefix":"10.47162","volume":"65","author":[{"name":"Discipline of Plastic and Reconstructive Surgery, Department 11, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Burn Centre, Bucharest Emergency Clinical Hospital, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza-Maria","family":"Bordeanu-Diaconescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Grama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Burn Centre, Bucharest Emergency Clinical Hospital, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Grosu-Bularda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Discipline of Plastic and Reconstructive Surgery, Department 11, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Frunz\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Discipline of Plastic and Reconstructive Surgery, Department 11, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Burn Centre, Bucharest Emergency Clinical Hospital, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103t\u0103lina-\u015etefania","family":"Dumitru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Discipline of Plastic and Reconstructive Surgery, Department 11, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela-Cristina","family":"Andrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Discipline of Plastic and Reconstructive Surgery, Department 11, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmin-Antoniu","family":"Creang\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pathology, Bucharest Emergency Clinical Hospital, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiberiu-Paul","family":"Neagu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Discipline of Plastic and Reconstructive Surgery, Department 11, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Burn Centre, Bucharest Emergency Clinical Hospital, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioan","family":"Lasc\u0103r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Discipline of Plastic and Reconstructive Surgery, Department 11, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26736","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina (Kaunas), 2021, 57(9):895. https:\/\/doi.org\/10.3390\/medicina57090895","DOI":"10.3390\/medicina57090895"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Bettencourt AP, Romanowski KS, Joe V, Jeng J, Carter JE, Cartotto R, Craig CK, Fabia R, Vercruysse GA, Hickerson WL, Liu Y, Ryan CM, Schulz JT. Updating the burn center referral criteria: results from the 2018 eDelphi Consensus Study. J Burn Care Res, 2020, 41(5):1052-1062. https:\/\/doi.org\/10.1093\/jbcr\/iraa038","DOI":"10.1093\/jbcr\/iraa038"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, Mozingo DW, Yowler CJ, Sheridan RL, Ahrenholz DH, Caruso DM, Foster KN, Kagan RJ, Voigt DW, Purdue GF, Hunt JL, Wolf S, Molitor F. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil, 2002, 23(2):87-96. https:\/\/doi.org\/10.1097\/00004630-200203000-00004","DOI":"10.1097\/00004630-200203000-00004"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg, 1998, 102(4):1018-1022. https:\/\/doi.org\/10.1097\/00006534-199809040-00014","DOI":"10.1097\/00006534-199809040-00014"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol, 2005, 153(2):241-253. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06721.x","DOI":"10.1111\/j.1365-2133.2005.06721.x"},{"key":"ref5","unstructured":"[6] Oakley AM, Krishnamurthy K. Stevens-Johnson syndrome. 2023 Apr 10. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, USA, 2024 Jan-."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"[7] Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res, 2008, 29(5):706-712. https:\/\/doi.org\/10.1097\/BCR.0b013e3181848bb1","DOI":"10.1097\/BCR.0b013e3181848bb1"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"[8] Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol, 1956, 68(11):355-361. https:\/\/doi.org\/10.1111\/j.1365-2133.1956.tb12766.x","DOI":"10.1111\/j.1365-2133.1956.tb12766.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol, 2003, 162(5):1515-1520. https:\/\/doi.org\/10.1016\/S0002-9440(10)64284-8","DOI":"10.1016\/S0002-9440(10)64284-8"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Hoetzenecker W, Mehra T, Saulite I, Glatz M, Schmid-Grendelmeier P, Guenova E, Cozzio A, French LE. Toxic epidermal necrolysis. F1000Res, 2016, 5:F1000. https:\/\/doi.org\/10.12688\/f1000research.7574.1","DOI":"10.12688\/f1000research.7574.1"},{"key":"ref10","unstructured":"[11] Labib A, Milroy C. Toxic epidermal necrolysis. 2023 May 8. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, USA, 2024 Jan-."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Shen MH, Liu MT, Chung WH, Lu CW. Toxic epidermal necrolysis induced by human herpesvirus 7 treated with a tumor necrosis factor-\u03b1 inhibitor. J Dermatol, 2020, 47(10):1179-1181. https:\/\/doi.org\/10.1111\/1346-8138.15493","DOI":"10.1111\/1346-8138.15493"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Shear NH, Dodiuk-Gad RP (eds). Advances in diagnosis and management of cutaneous adverse drug reactions: current and future trends. 1st edition, Adis, Singapore, 2019. https:\/\/doi.org\/10.1007\/978-981-13-1489-6","DOI":"10.1007\/978-981-13-1489-6"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"[14] Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol, 2011, 7(6):803-813; quiz 814-815. https:\/\/doi.org\/10.1586\/eci.11.66","DOI":"10.1586\/eci.11.66"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"[15] Finkelstein Y, Macdonald EM, Li P, Hutson JR, Juurlink DN. Recurrence and mortality following severe cutaneous adverse reactions. JAMA, 2014, 311(21):2231-2232. https:\/\/doi.org\/10.1001\/jama.2014.839","DOI":"10.1001\/jama.2014.839"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC; RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol, 2013, 133(5):1197-204. https:\/\/doi.org\/10.1038\/jid.2012.510","DOI":"10.1038\/jid.2012.510"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Wu J, Lee YY, Su SC, Wu TS, Kao KC, Huang CC, Chang WC, Yang CH, Chung WH. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. Br J Dermatol, 2015, 173(5):1224-1231. https:\/\/doi.org\/10.1111\/bjd.14052","DOI":"10.1111\/bjd.14052"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Chahal D, Aleshin M, Turegano M, Chiu M, Worswick S. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. Dermatol Online J, 2018, 24(1):13030\/qt7qn5268s.","DOI":"10.5070\/D3241037941"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Lin M, Gong T, Ruan S, Lv X, Chen R, Su X, Cheng B, Ji C. Emerging insights into Stevens-Johnson syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor and tumor-targeted therapy. J Inflamm Res, 2024, 17:2337-2351. https:\/\/doi.org\/10.2147\/JIR.S454673","DOI":"10.2147\/JIR.S454673"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology, 2005, 64(7):1134-1138. https:\/\/doi.org\/10.1212\/01.WNL.0000156354.20227.F0","DOI":"10.1212\/01.WNL.0000156354.20227.F0"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Sachs B, R\u00f6nnau AC, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine and toxic epidermal necrolysis. Lancet, 1996, 348(9041):1597. https:\/\/doi.org\/10.1016\/S0140-6736(05)66227-7","DOI":"10.1016\/S0140-6736(05)66227-7"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol, 2008, 128(1):35-44. https:\/\/doi.org\/10.1038\/sj.jid.5701033","DOI":"10.1038\/sj.jid.5701033"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Jan V, Toledano C, Machet L, Machet MC, Vaillant L, Lorette G. Stevens-Johnson syndrome after Sertraline. Acta Derm Venereol, 1999, 79(5):401. https:\/\/doi.org\/10.1080\/000155599750010472","DOI":"10.1080\/000155599750010472"},{"key":"ref23","unstructured":"[24] Bodokh I, Lacour JP, Rosenthal E, Chichmanian RM, Perrin C, Vitetta A, Ortonne JP. Syndrome de Lyell ou n\u00e9crolyse \u00e9pidermique toxique et syndrome de Stevens-Johnson apr\u00e8s traitement par Fluox\u00e9tine [Lyell syndrome or toxic epidermal necrolysis and Stevens-Johnson syndrome after treatment with Fluoxetine]. Therapie, 1992, 47(5):441."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med, 2008, 14(12):1343-1350. https:\/\/doi.org\/10.1038\/nm.1884","DOI":"10.1038\/nm.1884"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"[26] Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med, 2009, 151(7):514-515. https:\/\/doi.org\/10.7326\/0003-4819-151-7-200910060-00016","DOI":"10.7326\/0003-4819-151-7-200910060-00016"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Fujita Y, Yoshioka N, Abe R, Murata J, Hoshina D, Mae H, Shimizu H. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol, 2011, 65(1):65-68. https:\/\/doi.org\/10.1016\/j.jaad.2010.04.042","DOI":"10.1016\/j.jaad.2010.04.042"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Nakajima S, Watanabe H, Tohyama M, Sugita K, Iijima M, Hashimoto K, Tokura Y, Nishimura Y, Doi H, Tanioka M, Miyachi Y, Kabashima K. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol, 2011, 147(9):1110-1112. https:\/\/doi.org\/10.1001\/archdermatol.2011.239","DOI":"10.1001\/archdermatol.2011.239"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science, 1998, 282(5388):490-493. https:\/\/doi.org\/10.1126\/science.282.5388.490","DOI":"10.1126\/science.282.5388.490"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol, 2013, 69(2):173.e1-173.13; quiz 185-186. https:\/\/doi.org\/10.1016\/j.jaad.2013.05.003","DOI":"10.1016\/j.jaad.2013.05.003"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"[31] Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428(6982):486. https:\/\/doi.org\/10.1038\/428486a","DOI":"10.1038\/428486a"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"[32] Fan WL, Shiao MS, Hui RCY, Su SC, Wang CW, Chang YC, Chung WH. HLA association with drug-induced adverse reactions. J Immunol Res, 2017, 2017:3186328. https:\/\/doi.org\/10.1155\/2017\/3186328","DOI":"10.1155\/2017\/3186328"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"[33] Sakai Y, Nagamine Y, Yokose M, Yokoyama N, Yoshida T, Kashiwagi S, Takaki S, Goto T. Clinical features and prognosis of toxic epidermal necrolysis requiring intensive care: a retrospective descriptive single-center study. Burns Open, 2023, 7(4):139-45. https:\/\/doi.org\/10.1016\/j.burnso.2023.09.001","DOI":"10.1016\/j.burnso.2023.09.001"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, Touraine R. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol, 1987, 123(9):1160-1165. https:\/\/doi.org\/10.1001\/archderm.123.9.1160","DOI":"10.1001\/archderm.123.9.1160"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","unstructured":"[35] Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol, 1993, 129(1):92-96.","journal-title":"Arch Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int, 2006, 55(1):9-16. https:\/\/doi.org\/10.2332\/allergolint.55.9","DOI":"10.2332\/allergolint.55.9"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"[37] Brown CS, Defazio JR, An G, O'Connor A, Whitcomb E, Hart J, Gottlieb LJ. Toxic epidermal necrolysis with gastrointestinal involvement: a case report and review of the literature. J Burn Care Res, 2017, 38(1):e450-e455. https:\/\/doi.org\/10.1097\/BCR.0000000000000336","DOI":"10.1097\/BCR.0000000000000336"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"[38] Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, Ikezawa Z, Hashimoto K, Kinoshita S. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology, 2009, 116(4):685-690. https:\/\/doi.org\/10.1016\/j.ophtha.2008.12.048","DOI":"10.1016\/j.ophtha.2008.12.048"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"[39] Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea, 2007, 26(2):123-129. https:\/\/doi.org\/10.1097\/ICO.0b013e31802eb264","DOI":"10.1097\/ICO.0b013e31802eb264"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"[40] Schmidt-Westhausen A, Gr\u00fcnewald T, Reichart PA, Pohle HD. Oral manifestations of toxic epidermal necrolysis (TEN) in patients with AIDS: report of five cases. Oral Dis, 1998, 4(2):90-94. https:\/\/doi.org\/10.1111\/j.1601-0825.1998.tb00263.x","DOI":"10.1111\/j.1601-0825.1998.tb00263.x"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"[41] Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med, 1994, 331(19):1272-1285. https:\/\/doi.org\/10.1056\/NEJM199411103311906","DOI":"10.1056\/NEJM199411103311906"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"[42] Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol, 2007, 56(2):181-200. https:\/\/doi.org\/10.1016\/j.jaad.2006.04.048","DOI":"10.1016\/j.jaad.2006.04.048"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"[43] Estrella-Alonso A, Aramburu JA, Gonz\u00e1lez-Ruiz MY, Cachafeiro L, S\u00e1nchez MS, Lorente JA. Toxic epidermal necrolysis: a paradigm of critical illness. Rev Bras Ter Intensiva, 2017, 29(4):499-508. https:\/\/doi.org\/10.5935\/0103-507X.20170075","DOI":"10.5935\/0103-507X.20170075"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"[44] Surowiecka A, Bara\u0144ska-Rybak W, Stru\u017cyna J. Multidisciplinary treatment in toxic epidermal necrolysis. Int J Environ Res Public Health, 2023, 20(3):2217. https:\/\/doi.org\/10.3390\/ijerph20032217","DOI":"10.3390\/ijerph20032217"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"[45] Rzany B, Hering O, Mockenhaupt M, Schr\u00f6der W, Goerttler E, Ring J, Sch\u00f6pf E. Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol, 1996, 135(1):6-11.","DOI":"10.1111\/j.1365-2133.1996.tb03598.x"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"[46] Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol, 2000, 115(2):149-153. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00061.x","DOI":"10.1046\/j.1523-1747.2000.00061.x"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"[47] Noe MH, Rosenbach M, Hubbard RA, Mostaghimi A, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Hughey LC, Kaffenberger BH, Kroshinsky D, Kwong BY, Miller DD, Musiek A, Ortega-Loayza AG, Sharon VR, Shinkai K, Summers EM, Wanat KA, Wetter DA, Worswick S, Margolis DJ, Gelfand JM, Micheletti RG. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis - ABCD-10. JAMA Dermatol, 2019, 155(4):448-454. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5605","DOI":"10.1001\/jamadermatol.2018.5605"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"[48] Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis, 2010, 5:39. https:\/\/doi.org\/10.1186\/1750-1172-5-39","DOI":"10.1186\/1750-1172-5-39"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"[49] Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol, 2000, 136(3):323-327. https:\/\/doi.org\/10.1001\/archderm.136.3.323","DOI":"10.1001\/archderm.136.3.323"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"[50] Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JKG, Setterfield J, Bunker CB, Ardern-Jones MR, Watson KMT, Wong GAE, Philippidou M, Vercueil A, Martin RV, Williams G, Shah M, Brown D, Williams P, Mohd Mustapa MF, Smith CH. UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg, 2016, 69(6):e119-e153. https:\/\/doi.org\/10.1016\/j.bjps.2016.01.034","DOI":"10.1016\/j.bjps.2016.01.034"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"[51] Bordeanu-Diaconescu EM, Grosu-Bularda A, Frunza A, Grama S, Andrei MC, Neagu TP, Lascar I, Hariga CS. Diagnostic and prognostic value of thrombocytopenia in severe burn injuries. Diagnostics (Basel), 2024, 14(6):582. https:\/\/doi.org\/10.3390\/diagnostics14060582","DOI":"10.3390\/diagnostics14060582"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"[52] Britton GW, Wiggins AR, Halgas BJ, Cancio LC, Chung KK. Critical care of the burn patient. Surg Clin North Am, 2023, 103(3):415-426. https:\/\/doi.org\/101016\/j.suc.2023.01.005","DOI":"10.1016\/j.suc.2023.01.005"},{"key":"ref52","unstructured":"[53] Roujeau JC, Revuz J. Intensive care in dermatology. In: Champion RH, Pye RJ (eds). Recent advances in dermatology. Churchill Livingstone, Edinburgh, UK, 1990, 85-99."},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"[54] Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med, 2010, 36(1):22-32. https:\/\/doi.org\/10.1007\/s00134-009-1659-1","DOI":"10.1007\/s00134-009-1659-1"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"[55] Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J, 2002, 8(1):5.","DOI":"10.5070\/D397D8T291"},{"issue":"16","key":"ref55","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1001\/jama.1987.03390160093035","article-title":"Burn treatment for the unburned","volume":"257","author":"BA Jr","year":"1987","unstructured":"[56] Pruitt BA Jr. Burn treatment for the unburned. JAMA, 1987, 257(16):2207-2208.","journal-title":"JAMA"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"[57] Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C, Roupie E, Revuz J, Roujeau JC. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med, 1997, 23(12):1237-1244. https:\/\/doi.org\/10.1007\/s001340050492","DOI":"10.1007\/s001340050492"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"[58] de Prost N, Ingen-Housz-Oro S, Duong TA, Valeyrie-Allanore L, Legrand P, Wolkenstein P, Brochard L, Brun-Buisson C, Roujeau JC. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore), 2010, 89(1):28-36. https:\/\/doi.org\/10.1097\/MD.0b013e3181ca4290","DOI":"10.1097\/MD.0b013e3181ca4290"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"[59] Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, Ikezawa Z, Aihara M. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients - treatment and outcome. Allergol Int, 2016, 65(1):74-81. https:\/\/doi.org\/10.1016\/j.alit.2015.09.001","DOI":"10.1016\/j.alit.2015.09.001"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"[60] de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, Van Nhieu JT, Duong TA, Chosidow O, Wolkenstein P, Brun-Buisson C, Ma\u00eetre B. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med, 2014, 42(1):118-128. https:\/\/doi.org\/10.1097\/CCM.0b013e31829eb94f","DOI":"10.1097\/CCM.0b013e31829eb94f"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"[61] Phan K, Oh LJ, Issler-Fisher A, Rao A, Wong EH, Maitz P. Ventilatory support in Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. J Dermatolog Treat, 2022, 33(1):525-530. https:\/\/doi.org\/10.1080\/09546634.2020.1770173","DOI":"10.1080\/09546634.2020.1770173"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"[62] Chen CB, Hsu TH, Chung-Yee Hui R, Lu CW, Chen WT, Chiang PH, Wang CW, Chuang SS, Yang JY, Yang SY, Chang SY, Hsiao YC, Kao KC, Hu HC, Wu TS, Hsu CW, Hui-Kang Ma D, Chen SY, Tian YC, Cheng CY, Chen CH, Chi MH, Wu MY, Liu RF, Wang CH, Chang YC, Lin JY, Ho HC, Yu-Wei Lin Y, Chang CJ, Lin YJ, Ku CL, Hung SI, Chung WH; Taiwan Severe Cutaneous Adverse Reaction Consortium. Disseminated intravascular coagulation in Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol, 2021, 84(6):1782-1791. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.065","DOI":"10.1016\/j.jaad.2020.08.065"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"[63] Ball RL, Keyloun JW, Brummel-Ziedins K, Orfeo T, Palmieri TL, Johnson LS, Moffatt LT, Pusateri AE, Shupp JW. Burn-induced coagulopathies: a comprehensive review. Shock, 2020, 54(2):154-167. https:\/\/doi.org\/10.1097\/SHK.0000000000001484","DOI":"10.1097\/SHK.0000000000001484"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"[64] Tichil I, Rosenblum S, Paul E, Cleland H. Treatment of anaemia in patients with acute burn injury: a study of blood transfusion practices. J Clin Med, 2021, 10(3):476. https:\/\/doi.org\/10.3390\/jcm10030476","DOI":"10.3390\/jcm10030476"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"[65] Bordeanu-Diaconescu EM, Grosu-Bularda A, Frunza A, Grama S, Andrei MC, Neagu TP, Hariga CS, Lascar I. Venous thromboembolism in burn patients: a 5-year retrospective study. Medicina (Kaunas), 2024, 60(2):258. https:\/\/doi.org\/10.3390\/medicina60020258","DOI":"10.3390\/medicina60020258"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"[66] El-Azhary RA, Nowsheen S, Gibson LE, DiCaudo DJ. Disseminated intravascular coagulopathy: a complication of Stevens-Johnson syndrome\/toxic epidermal necrolysis. Int J Dermatol, 2021, 60(2):185-189. https:\/\/doi.org\/10.1111\/ijd.15370","DOI":"10.1111\/ijd.15370"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"[67] Rajaratnam R, Mann C, Balasubramaniam P, Marsden JR, Taibjee SM, Shah F, Lim R, Papini R, Moiemen N, Lewis H. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clin Exp Dermatol, 2010, 35(8):853-862. https:\/\/doi.org\/10.1111\/j.1365-2230.2010.03826.x","DOI":"10.1111\/j.1365-2230.2010.03826.x"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"[68] Ririe MR, Blaylock RC, Morris SE, Jung JY. Intravenous immune globulin therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis. J Am Acad Dermatol, 2013, 69(2):221-225. https:\/\/doi.org\/10.1016\/j.jaad.2013.04.017","DOI":"10.1016\/j.jaad.2013.04.017"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"[69] Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE; TEN-IVIG Study Group. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol, 2003, 139(1):26-32. https:\/\/doi.org\/10.1001\/archderm.139.1.26","DOI":"10.1001\/archderm.139.1.26"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"[70] Papp A, Sikora S, Evans M, Song D, Kirchhof M, Miliszewski M, Dutz J. Treatment of toxic epidermal necrolysis by a multi-disciplinary team. A review of literature and treatment results. Burns, 2018, 44(4):807-815. https:\/\/doi.org\/10.1016\/j.burns.2017.10.022","DOI":"10.1016\/j.burns.2017.10.022"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"[71] Ng QX, De Deyn MLZQ, Venkatanarayanan N, Ho CYX, Yeo WS. A meta-analysis of Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Inflamm Res, 2018, 11:135-142. https:\/\/doi.org\/10.2147\/JIR.S160964","DOI":"10.2147\/JIR.S160964"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"[72] Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol, 2011, 38(3):236-245. https:\/\/doi.org\/10.1111\/j.1346-8138.2010.01154.x","DOI":"10.1111\/j.1346-8138.2010.01154.x"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"[73] Szczeklik W, Nowak I, Seczynska B, Sega A, Krolikowski W, Musial J. Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis. Ther Apher Dial, 2010, 14(3):354-357. https:\/\/doi.org\/10.1111\/j.1744-9987.2009.00800.x","DOI":"10.1111\/j.1744-9987.2009.00800.x"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"[74] Ko\u0161t\u00e1l M, Bl\u00e1ha M, L\u00e1nsk\u00e1 M, Ko\u0161t\u00e1lov\u00e1 M, Bl\u00e1ha V, \u0160tep\u00e1nov\u00e1 E, Mal\u00fd J. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases. J Clin Apher, 2012, 27(4):215-220. https:\/\/doi.org\/10.1002\/jca.21213","DOI":"10.1002\/jca.21213"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"[75] Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol, 2017, 153(6):514-522. https:\/\/doi.org\/10.1001\/jamadermatol.2016.5668","DOI":"10.1001\/jamadermatol.2016.5668"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"[76] Ye Z, Li C, Zhang H, Zhang C, Lu X. Effectiveness and safety of early short-course, moderate- to high-dose glucocorticoids for the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a retrospective study. Clin Cosmet Investig Dermatol, 2022, 15:1979-1990. https:\/\/doi.org\/10.2147\/CCID.S378106","DOI":"10.2147\/CCID.S378106"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"[77] Harris V, Jackson C, Cooper A. Review of toxic epidermal necrolysis. Int J Mol Sci, 2016, 17(12):2135. https:\/\/doi.org\/10.3390\/ijms17122135","DOI":"10.3390\/ijms17122135"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"[78] Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, Heng WJ. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy, 2007, 62(5):527-531. https:\/\/doi.org\/10.1111\/j.1398-9995.2006.01295.x","DOI":"10.1111\/j.1398-9995.2006.01295.x"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"[79] Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimar\u00e3es J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology, 2003, 207(1):33-36. https:\/\/doi.org\/10.1159\/000070938","DOI":"10.1159\/000070938"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"[80] Sheridan RL, Schulz JT, Ryan CM, Schnitzer JJ, Lawlor D, Driscoll DN, Donelan MB, Tompkins RG. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics, 2002, 109(1):74-78. https:\/\/doi.org\/10.1542\/peds.109.1.74","DOI":"10.1542\/peds.109.1.74"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"[81] Ingen-Housz-Oro S, Schmidt V, Ameri MM, Abe R, Brassard A, Mostaghimi A, Paller AS, Romano A, Didona B, Kaffenberger BH, Ben Said B, Thong BYH, Ramsay B, Brezinova E, Milpied B, Mortz CG, Chu CY, Sotozono C, Gueudry J, Fortune DG, Dridi SM, Tartar D, Do-Pham G, Gabison E, Phillips EJ, Lewis F, Salavastru C, Horvath B, Dart J, Setterfield J, Newman J, Schulz JT, Delcampe A, Brockow K, Seminario-Vidal L, J\u00f6rg L, Watson MP, Gon\u00e7alo M, Lucas M, Torres M, Noe MH, Hama N, Shear NH, O'Reilly P, Wolkenstein P, Romanelli P, Dodiuk-Gad RP, Micheletti RG, Tiplica GS, Sheridan R, Rauz S, Ahmad S, Chua SL, Flynn TH, Pichler W, Le ST, Maverakis E, Walsh S, French LE, Br\u00fcggen MC. Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus. Orphanet J Rare Dis, 2023, 18(1):33. https:\/\/doi.org\/10.1186\/s13023-023-02631-7\"","DOI":"10.1186\/s13023-023-02631-7"}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T10:55:14Z","timestamp":1740653714000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/65\/4\/23\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,13]]},"published-print":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.65.4.23","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}